# BOONE CAPITAL MANAGEMENT LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1882053. Source: https://holderbook.com/funds/1882053-boone-capital-management-llc/

- Reported value: $427.5M
- Positions: 16
- Weight of the ten largest: 83.0%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| TELEFLEX INCORPORATED | [TFX](https://holderbook.com/stocks/TFX/) | $49.1M | 387,388 | 11.5% | 2 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $48.7M | 415,641 | 11.4% | 12 |
| THE CIGNA GROUP | [CI](https://holderbook.com/stocks/CI/) | $43.9M | 159,290 | 10.3% | 15 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $41.2M | 519,977 | 9.6% | 4 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $36.9M | 88,687 | 8.6% | 5 |
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $33.4M | 583,219 | 7.8% | 6 |
| GUARDIAN PHARMACY SVCS INC | [GRDN](https://holderbook.com/stocks/GRDN/) | $29.8M | 711,939 | 7.0% | 2 |
| VESTIS CORPORATION | [VSTS](https://holderbook.com/stocks/VSTS/) | $27.6M | 1,900,140 | 6.5% | 1 |
| BRIDGEBIO PHARMA INC | [BBIO](https://holderbook.com/stocks/BBIO/) | $25.3M | 339,720 | 5.9% | 4 |
| PENNANT GROUP INC | [PNTG](https://holderbook.com/stocks/PNTG/) | $19.1M | 515,818 | 4.5% | 1 |
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $14.9M | 615,287 | 3.5% | 1 |
| KODIAK SCIENCES INC | [KOD](https://holderbook.com/stocks/KOD/) | $14.7M | 378,010 | 3.4% | 4 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $14.2M | 455,605 | 3.3% | 1 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $13.0M | 113,173 | 3.0% | 1 |
| CULLINAN THERAPEUTICS INC | [CGEM](https://holderbook.com/stocks/CGEM/) | $12.8M | 704,442 | 3.0% | 1 |
| ADLAI NORTYE LTD | [ANL](https://holderbook.com/stocks/ANL/) | $3.0M | 258,390 | 0.7% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +11.9% | +14.8% | -2.9% | 100% |
| Q1 2026 | -0.3% | -4.6% | +4.3% | 95% |
| Q4 2025 | +16.4% | +2.4% | +14.0% | 100% |
| Q3 2025 | +7.5% | +7.8% | -0.4% | 100% |
| Q2 2025 | -4.6% | +10.5% | -15.1% | 100% |
| Q1 2025 | -0.9% | -4.6% | +3.7% | 100% |
| Q4 2024 | -5.4% | +2.1% | -7.6% | 100% |
| Q3 2024 | +11.7% | +5.4% | +6.3% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $427.5M | 16 |
| Q1 2026 | $326.4M | 13 |
| Q4 2025 | $318.6M | 15 |
| Q3 2025 | $305.0M | 16 |
| Q2 2025 | $233.2M | 11 |
| Q1 2025 | $293.8M | 12 |
| Q4 2024 | $296.5M | 13 |
| Q3 2024 | $385.8M | 17 |
| Q2 2024 | $383.4M | 19 |
| Q1 2024 | $494.4M | 21 |
| Q4 2023 | $428.4M | 21 |
| Q3 2023 | $317.0M | 13 |